Sandwich, Kent, UK / 26th June 2024 / Discovery Park welcomed experts in healthy ageing to its Innovation Summit on 20th June, calling for the life science network in Kent to join forces to make the county a leader in healthy ageing and longevity.
Over 230 attendees came together at the one day event to discuss innovation in healthcare, taking a close look at trends in healthy ageing, developing more integrated care, and the role of digital collaboration in future healthcare delivery.
Press release
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
• Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer mouse model systems
• The collaboration will combine advanced in vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology for precision oncology medicines
Sandwich, Kent, UK / 18th June 2024 / Discovery Park, Kent’s thriving life science and innovation community, is preparing to welcome 300 healthcare innovators to its campus on Thursday 20th June for its second annual Innovation Summit, with only final spots remaining.
This year’s summit has a focus on innovation in healthcare, taking a close look at trends in healthy ageing, breakthroughs in medicine and life science, and the role of digital collaboration in future healthcare delivery.
On Wednesday 15th May, Pharmaron hosted the 3rd Chemistry for Life Science Symposium. Academic and industry experts presented on the leading edge of drug discovery and process chemistry with speakers Professor Robert Phipps (University of Cambridge), Professor Ross Denton (University of Nottingham), Dr Sarah Skerratt (CHARM Therapeutics), Dr David Wilson (AstraZeneca), Dr Jeremy Parker (AstraZeneca) along with Dr Sébastien Campos (Pharmaron) and Dr Aaron Dumas (Pharmaron).
AMSBIO offers a range of kits, media and reagents enabling development of food in a way that is not wasteful of our natural resources and is not detrimental to the environment or consumer health.
Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development.
In this article, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, explores the potential of PDCs and their role in shaping the future of drug discovery.